Novavax surges after winning new order for COVID-19 vaccine

 

• Novavax (NASDAQ:NVAX) climbs +9.2% after announcing an agreement to supply 10.7M doses of its COVID-19 vaccine to the government of New Zealand.
• Per the agreement, the company is set to deliver the initial doses of the vaccine candidate, NVX-CoV2373, from mid-2021, subject to the approval of Medsafe, New Zealand’s regulatory agency.
• The recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M™ to boost the immune response against COVID-19 is currently undergoing a Phase 3 clinical trial in the UK.
• On the back of COVID-19 vaccine success, Novavax has surged a whopping 2930% during the year, far eclipsing the performance of front-runners, Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and BioNTech (NASDAQ:BNTX).
• https://seekingalpha.com/news/3645472-novavax-surges-9-after-winning-new-order-for-covidminus-19-vaccine